Zentalis Advances Azenosertib, But Enters Phase 3 Facing Adavosertib's 14.9-Month Survival Benchmark

Zentalis to Present Azenosertib OS Data and Phase 3 Design at ESMO 2026

Zentalis Pharmaceuticals announced two presentations at the European Society for Medical Oncology (ESMO) Congress 2026. A rapid oral presentation will feature overall survival data from the DENALI Part 1b study of azenosertib in Cyclin E1-positive platinum-resistant ovarian cancer (PROC). Additionally, a trial-in-progress poster will detail the ASPENOVA Phase 3 study, which compares azenosertib monotherapy to standard-of-care chemotherapy in the same biomarker-selected patient population. These presentations underscore Zentalis's focus on advancing azenosertib as a biomarker-driven treatment for PROC patients with high unmet needs, highlighting its potential for long-term survival benefits.

• Zentalis will present overall survival (OS) results from the DENALI Part 1b study (GOG-3066) as a rapid oral presentation at ESMO 2026 on October 23. This data is expected to showcase long-term survival benefits of azenosertib in patients with Cyclin E1-positive platinum-resistant ovarian cancer (PROC), supporting the company's strategy for registration-intended monotherapy trials in this biomarker-selected population.
• A trial-in-progress poster presentation on October 26 will detail the ASPENOVA study, a Phase 3 randomized, confirmatory clinical trial. This trial is designed to enroll approximately 420 patients with Cyclin E1-positive PROC, comparing azenosertib monotherapy (400mg QD 5:2) against investigator's choice of standard-of-care chemotherapy. The primary endpoint is progression-free survival (PFS), with key secondary endpoints including overall survival (OS) and overall response rate (ORR).
• Azenosertib is an investigational, potentially first-in-class, selective, and orally bioavailable WEE1 inhibitor. It is in late-stage development for Cyclin E1-positive platinum-resistant ovarian cancer (PROC), a population comprising approximately 50% of PROC patients with no specific approved treatment. Cyclin E1 protein overexpression serves as a sensitive and specific predictive biomarker for identifying patients who may benefit from azenosertib treatment.

Azenosertib's Clinical Strategy: DENALI and ASPENOVA Trial Designs

CCNE1 amplification is a key molecular driver in a subset of high-grade serous ovarian cancers, where it is strongly associated with primary platinum resistance and homologous recombination (HR) proficiency. This amplification leads to increased replication stress, creating a therapeutic vulnerability that can be targeted by DNA damage response (DDR) inhibitors. Key clinical studies have explored this biology, either by targeting the vulnerability directly or by evaluating the prognostic impact of CCNE1 status in the platinum-resistant setting.

Addressing Unmet Needs in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer

Cyclin E1 (CCNE1)-positive, platinum-resistant ovarian cancer has emerged as a distinct molecular subgroup with limited therapeutic options and a poor prognosis, particularly among BRCA wild-type/HR-proficient high-grade serous ovarian carcinoma (HGSOC) patients. Recent literature underscores both the biological rationale for targeting this population and the growing pipeline of CDK2, WEE1, and CDK4/6 inhibitor strategies designed to address this gap.

• HR-proficient/BRCA wild-type populations remain underserved: Roughly 50% of HGSC cases are HR-proficient, deriving minimal benefit from PARP inhibitors and exhibiting primary platinum resistance, shorter survival, and "cold" tumor immunophenotypes (fewer infiltrating lymphocytes, reduced PD-1/PD-L1 expression). There is a recognized need to include these patients more systematically in ovarian cancer trials with targeted analytic approaches.

• CCNE1 amplification as a defining biomarker: Observed in ~20–29% of HGSC cases, CCNE1 amplification is negatively correlated with BRCA1/2 mutations (p=0.001) and behaves as an independent oncogenic driver rather than a marker of broader genomic instability. It is associated with moderate chemotherapy sensitivity (defining an intermediate prognostic subgroup), underrepresentation among long-term survivors, and emerging validation via FISH (rho=0.93) alongside NGS-based detection.

• Discordance between genomic and protein-level CCNE1 expression: Notably, CCNE1 protein overexpression occurs without gene amplification in ~45% of cases, and IHC does not reliably predict taxane-platinum resistance—raising unresolved questions about the mechanistic drivers of CCNE1-associated tumorigenesis that warrant further investigation.

• CDK4/6 inhibitor resistance and selective populations for CDK2 inhibition: CCNE1 amplification has been identified as a predictor of resistance to palbociclib, whose clinical activity in unselected recurrent ovarian cancer populations remains modest (ORR ~10.5%, mPFS 3.2 months). Conversely, ~25% of ovarian cancers show coordinate cyclin E1/P16INK4A/RB expression, marking a subgroup exquisitely sensitive to selective CDK2 inhibitors such as BLU-222 and QR-6401, which uniquely inhibit both G1 and G2 cell-cycle phases.

• WEE1 inhibition as a targeted strategy: Azenosertib has shown strong preclinical activity in cyclin E1-high/CDK2-activated ovarian and uterine serous carcinoma models, driven by elevated baseline replication stress, with synergy across multiple chemotherapy classes. Early phase I clinical data support monotherapy activity in this biomarker-defined population.

• Combination approaches targeting DNA damage response and replication stress: Strategies combining CDK2 inhibitors with CDK4/6 inhibitors (synergistic) — but not WEE1 inhibitors (antagonistic) — are being explored, alongside novel agents like harmine, which suppresses HR-proficient, CCNE1-amplified cells and synergizes with olaparib in BRCA1/2 wild-type disease via CDK9-mediated inhibition of HR gene transcription.

• Low-grade serous ovarian cancer as a niche population: CDK4/6 inhibition (palbociclib) has demonstrated notable disease stabilization (>37 and >9 months in reported cases), suggesting this histologic subtype warrants dedicated further study.

• Emerging biomarker frameworks and clinical trial infrastructure: Composite biomarkers such as the Mutational Signature-Based BioMarker (MSBM), integrating BRCA status and mutational signature scores with CCNE1 amplification status, are being validated in trials like MSBM-OL and CHIVA to refine patient selection for PARP inhibitor maintenance and chemotherapy sequencing strategies in this hard-to-treat population.